Trial Profile
Non-Interventional Study To Investigate The Effectiveness Of Atezolizumab Under Real-World Conditions In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce)
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Apr 2019
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Bladder cancer; Renal cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- Acronyms Announce
- Sponsors Roche
- 17 Apr 2019 Status changed from active, no longer recruiting to discontinued.
- 01 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 22 Jan 2018 New trial record